Plant-Derived Bioactive Compounds for Premature Ovarian Insufficiency: Molecular Mechanisms, Bioavailability Challenges, and Translational Strategies
Molecules · 15.11.2026 · 31 (22) · 4124
DOI: 10.3390/molecules31224124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, online erschienen am 15.11.2026. Verfasst von Zhanyu Lin und 5 weiteren Autor:innen. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Province Traditional Chinese Medicine Science & Technology Project.
Abstract (Originalsprache)
Premature ovarian insufficiency (POI, formerly termed premature ovarian failure, POF; hereafter, POI is used throughout the manuscript) is a heterogeneous reproductive endocrine disorder characterized by impaired ovarian function before the age of 40 and is commonly associated with menstrual abnormalities, hypoestrogenism, and reduced fertility. Current therapeutic options can alleviate hormone-deficiency-related symptoms but remain limited in restoring ovarian reserve and fertility. Plant-derived bioactive compounds have attracted increasing attention because of their multitarget pharmacological activities and potential to modulate key pathological processes involved in POI. This review summarizes current evidence on the protective effects of plant-derived bioactive compounds in POI, with particular emphasis on granulosa cell apoptosis, oxidative stress, mitochondrial dysfunction, inflammatory signaling, cellular differentiation, and DNA damage repair. Evidence derived from chemotherapy-, radiation-, and aging-induced POI models is also discussed to highlight model-dependent differences in therapeutic responses. In addition, major pharmacokinetic barriers, including poor solubility, low oral bioavailability and metabolic instability, are critically examined. Emerging strategies such as chemical modification, nanocarriers, and phospholipid complexes may help improve drug exposure and delivery. However, much of the evidence remains preclinical, and clinical translation is constrained by insufficient pharmacokinetic characterization, limited safety data, formulation variability, and a lack of well-designed clinical trials. Further studies should therefore prioritize standardized compounds, mechanistically informed delivery systems, long-term safety evaluation, and rigorous clinical validation.
Förderung
- Shandong Province Traditional Chinese Medicine Science & Technology Project
Zitieren
APA
Lin, Z., Liu, R., Li, Y., Guo, Z., Wang, K., & Ma, F. (2026). Plant-Derived Bioactive Compounds for Premature Ovarian Insufficiency: Molecular Mechanisms, Bioavailability Challenges, and Translational Strategies. Molecules, 31(22), 4124. https://doi.org/10.3390/molecules31224124
Vancouver
Lin Z, Liu R, Li Y, Guo Z, Wang K, Ma F. Plant-Derived Bioactive Compounds for Premature Ovarian Insufficiency: Molecular Mechanisms, Bioavailability Challenges, and Translational Strategies. Molecules. 2026;31(22):4124. doi:10.3390/molecules31224124
BibTeX
@article{Lin2026,
author = {Lin, Zhanyu and Liu, Ruixin and Li, You and Guo, Zhengqi and Wang, Kexiang and Ma, Fengjun},
title = {Plant-Derived Bioactive Compounds for Premature Ovarian Insufficiency: Molecular Mechanisms, Bioavailability Challenges, and Translational Strategies},
journal = {Molecules},
year = {2026},
volume = {31},
number = {22},
pages = {4124},
doi = {10.3390/molecules31224124}
}
EUVIMED